COMMUNIQUÉS West-GlobeNewswire

Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates
08/05/2025
-- Initial data from Phase 1/2 trial of PM359 for p47 phox CGD expected in 2025 -- -- IND and/or CTA for PM577 for Wilson’s Disease on-track for 1H 2026 -- -- Unveiled potentially best-in-class program for AATD; IND and [...]
Vericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability Guidance
08/05/2025
Record First Quarter MACI Revenue of $46.3 Million and First Quarter Total Revenue of $52.6 Million Approximately 400 MACI Arthro Surgeons Trained to Date, with Year-to-Date Biopsy Growth Over 30% for Trained Surgeons [...]
OrganOx Announces Second Private Placement Closing, Investments by Intuitive Ventures and Terumo Ventures
08/05/2025
OrganOx to benefit from Intuitive Ventures’ and Terumo Ventures’ unique operating and clinical experience OXFORD, England and MADISON, N.J., May 08, 2025 (GLOBE NEWSWIRE) -- OrganOx Ltd., a leading organ medical [...]
Cognition Therapeutics Reports Topline Results Showing Oral Zervimesine (CT1812) Reduced Lesion Growth in Phase 2 Study in Geographic Atrophy
08/05/2025
Zervimesine treatment slowed the rate of GA lesion growth by 28.6% compared to placebo Observed GA lesion area was reduced by 28.2% at 18 months compared to placebo Dry AMD results validate zervimesine’s potential [...]
Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
08/05/2025
CORAL GABLES, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, or “the Company”), a clinical-stage biotechnology company committed to advancing innovative breakthrough [...]
Kamari Pharma Announces Presentations at the 82nd Annual Meeting of the Society for Investigative Dermatology and the International Pachyonychia Congenita Consortium Symposium
08/05/2025
Preclinical results presented demonstrate KM-023 is a highly effective and selective oral TRPV3 inhibitor KM-023 normalized cells proliferation and differentiation in 3D pachyonychia congenita skin model and [...]
Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
08/05/2025
- FDA (CDER) Type C meeting held in May 2025 for DYNE-101 in DM1 and Dyne plans to provide a regulatory update following receipt of meeting minutes - - Registrational Expansion Cohort of ACHIEVE Trial of DYNE-101 in DM1 [...]
Palvella Therapeutics to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025
08/05/2025
WAYNE, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients [...]
Cronos Group Reports 2025 First Quarter Results
08/05/2025
Net revenue in Q1 2025 increased by 28% year-over-year, 33% year-over-year net revenue growth on a constant currency basis PEACE NATURALS ® retained its position as the number one cannabis brand in Israe l 1 Industry- [...]
Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress
08/05/2025
On track to complete enrollment of the global Phase 3 HAELO study in hereditary angioedema (HAE) in the third quarter of 2025 Dosed first patient in the global Phase 3 MAGNITUDE-2 study evaluating nexiguran ziclumeran ( [...]
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results
08/05/2025
Updated Phase 2 data to be presented at ASCO for vilastobart, a tumor-activated, Fc-enhanced, anti-CTLA-4, in combination with atezolizumab in patients with metastatic microsatellite stable colorectal cancer (MSS CRC) [...]
Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update
08/05/2025
Dosing complete in the first two cohorts of INLIGHT trial in obesity of WVE-007 (INHBE siRNA), designed to induce healthy weight loss by reducing fat without impacting muscle; clinical data on track for 2H 2025 Dosing [...]
Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress™
08/05/2025
MASH Resolution Index (MASHResInd) model highly predictive of MASH resolution GAITHERSBURG, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing [...]
Wellgistics Health Secures $50M Credit Facility and Launches XRP-Powered Payment Initiative
08/05/2025
Tampa, FL, May 08, 2025 (GLOBE NEWSWIRE) -- Wellgistics Health, Inc. (NASDAQ: WGRX), a technology-first pharmaceutical distribution and healthcare infrastructure company, today announced a new initiative to pioneer the [...]
Axogen, Inc. Reports 2025 First Quarter Financial Results
08/05/2025
ALACHUA, Fla. and TAMPA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported [...]
Clearside Biomedical to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025
08/05/2025
ALPHARETTA, Ga., May 08, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye [...]
Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025
08/05/2025
WALTHAM, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that it will host a [...]
LENSAR Reports First Quarter 2025 Results and Provides Business Update
08/05/2025
14 ALLY Robotic Laser Cataract Systems™ (“ALLY Systems”) placed in 1Q 2025 with an additional backlog of 24 systems pending installation as of March 31, 2025 34% Revenue growth over the first quarter 2024 and 22% [...]
HilleVax Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress
08/05/2025
$159.5 million of cash, cash equivalents and marketable securities as of March 31, 2025 The company is exploring the potential for continued development of its norovirus vaccine candidates in adults as well as business [...]

Pages